AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
← catalyst calendarNCT07215585 · readout in 1,390 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
420estimated
Sites
68
Countries
Australia, Belgium, Brazil +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-11 | actual | When the study began enrolling |
| Primary completion | 2030-06-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-07-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Large B-cell Lymphoma
Interventions
- Drug: AZD0486 — also filed as TNB-486
- Drug: R-mini-CHOP
Primary outcomes
what the primary-completion date above is the date OFSRI - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.
measured Up to 1 year
SRI - Tolerability evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.
measured Up to 1 year
SRI - Determination of the recommended Phase III dose (RP3D)
measured Up to 1 year
Phase 3 - To demonstrate the superiority of R-mini-CHOP x2 followed by AZD0486 compared to R-mini-CHOP x6 regimen.
measured Up to 7 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed